Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
Authors:
- 10 August 2017
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Abstract
Historically, patients with kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway have been grouped into clinical syndromes, C3 glomerulopathy (C3GN/DDD) and thrombotic microangiopathy (TMA), specifically atypical haemolytic uremic syndrome (aHUS). Recent data suggested that these diseases share a common pathophysiology and that patients can transition between glomerulopathies in this spectrum. Histopathologically, the main difference cited is the immunofluorescence (IF) findings, with C3 predominance in C3 glomerulopathy (compared with immunoglobulins and complements in immune complex-mediated membranoproliferative glomerulonephritis (MPGN)) and negative IF in TMA. We report a case in which a patient presented with hypertension, seizures, proteinuria, renal impairment and immune complex-mediated MPGN on kidney biopsy. Months later, she presented with classical TMA. She failed to respond to steroids and plasma exchange therapy but subsequently made a remarkable haematological and renal recovery after eculizumab treatment, thus supporting an underlying complement dysregulation and a diagnosis of aHUS.Keywords
This publication has 10 references indexed in Scilit:
- Kidney Disease Caused by Dysregulation of the Complement Alternative PathwayJournal of the American Society of Nephrology, 2015
- Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015American Journal of Kidney Diseases, 2015
- Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesKidney International, 2015
- Eculizumab in the Treatment of Membranoproliferative GlomerulonephritisNephron Clinical Practice, 2014
- Anti-Complement Therapy for Glomerular DiseasesAdvances in Chronic Kidney Disease, 2014
- Update on Membranoproliferative GNClinical Journal of the American Society of Nephrology, 2014
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathiesNature Reviews Nephrology, 2012
- TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trialsKidney International, 2009
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998